Floatz logo

Azacitidine

Acute Myeloid Leukemia With 11q23 Abnormalities

Northwestern UniversitySmall moleculePhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Acute Myeloid Leukemia With 11q23 Abnormalities cohort.

Asset / SponsorPhaseRating
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Etoposide
M.D. Anderson Cancer Center
Phase 3BBB
Cytarabine
Alice Mims
Phase 3BBB
Idarubicin
Bruno C. Medeiros
Phase 2BBB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Active
BBB
Indicative · Phase 2
73 / 100
View asset →
acute erythroid leukemiaActive
BB
Indicative · Phase 2
71 / 100
View asset →
angioimmunoblastic T-cell lymphomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →